-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: immediate news
On June 10, Verona Pharma (Verona for short) and Nuance Pharma announced that the two parties have reached an agreement under which Verona Pharma will authorize the latter to be responsible for the development and commercialization of ensifentrine in Greater China
.
According to the terms of the agreement, Verona has granted Yourui Medicine the exclusive right to clinical development and commercialization of ensifentrine in Greater China
.
In return, Verona will receive a down payment of USD 25 million and Urui Biotech (the parent company of Urui Pharmaceuticals) currently worth approximately $15 million of equity
Ensifentrine (RPL554) is a potential "first-in-class" inhaled phosphodiesterase-3 and -4 (PDE3 and PDE4) dual inhibitor new drug.
This dual inhibition mechanism enables it to be achieved simultaneously with a single compound Bronchiectasis and anti-inflammatory effect
.
Ensifentrine can also activate the cystic fibrosis transmembrane transduction regulator (CFTR), which helps reduce mucus viscosity and improve mucociliary clearance
In the Phase 2 clinical study conducted by Verona on patients with moderate to severe COPD, ensifentrine had significant and clinically significant improvements in lung function and symptoms including dyspnea
.
In addition, nebulized ensifentrine can further improve the lung function of patients with COPD treated with standard short-acting and long-acting bronchodilators (including dual/triple therapy bronchodilators) and reduce lung volume
Note: The original text has been deleted
Reference materials:
[1] Verona Pharma and Yourui Pharmaceutical announced a strategic cooperation of US$219 million to develop and commercialize Ensifentrine in Greater China.
